Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Obesity's hidden toll: gulf study reveals costly health complications

NCT ID NCT06288399

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined how often adults with obesity in the Gulf region have related health issues like diabetes, high blood pressure, and heart disease. Researchers also looked at the medical costs and healthcare use tied to these conditions. The goal was to better understand the real-world impact of obesity on health and the economy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,316 people

The number who actually took part.

Started

Dec 2023

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with diagnosis of obesity and obesity-related comorbidities

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Local national (male or female) of Arab ethnicity, age above or equal to 18 years at index date 2. Primary or secondary diagnosis of obesity (BMI above or equal to 30 kg/m2) at index date 3. Minimum of 1 visit with BMI recorded between months 1 and 6 following index date, and minimum of 1 visit with BMI recorded between months 7 and 12 following index date. There should be a minimum time gap of 3 months between the BMI records and the BMI must be above or equal 30 kg/m2 at each visit. If there are multiple visits during the 12-month observation period, then a mean BMI above or equal 30 kg/m2 must be maintained during the observation period. Exclusion Criteria: 1. Previous participation in this study. Participation is defined as having collected data of the participants in this study already. 2. Participation in an interventional trial during the 12-month observation period 3. Conditions associated with unintentional weight change 4. Participants who underwent bariatric surgery within 18 months prior to the index date 5. Participants with non-ambulatory disability diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Al-Adan Hospital

    Hadiya, 52700, Kuwait

  • Al-Amiri Hospital

    Kuwait City, 13001, Kuwait

  • Farwaniya Hospital

    Farwaniya, 85000, Kuwait

  • Hamad General Hospital

    Doha, 122104, Qatar

  • National Diabetes and Endocrine Center

    Muscat, 113, Oman

  • PHCC

    Doha, 122104, Qatar

  • Samail Polyclinic

    Samail, 620, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.